The CGRP Receptor and Migraines.
A video review from Eli Lilly. Venture 17 has no economic relationship with Eli Lilly. This video is for educational purposes only.
Click this image to view the video.
Venetoclax monotherapy appears to improve outcomes in some patients with acute
myelogenous leukemia (AML), according to a phase 2, single-arm study.
"This study included patients that
were in categories that are difficult to treat - relapsed, refractory, and/or
elderly and deemed medically unfit to receive induction therapy," Dr.
Anthony Letai from Dana-Farber Cancer Institute in Boston told Reuters Health
"The fact that some of these
patients had leukemias that were relapsed or refractory to very tough regimens,
including regimens that require multi-week inpatient hospital stays, but
nonetheless responded to an oral outpatient therapy taken once a day was a very
interesting result," he said.
Von Willebrand disease (VWD) is an inherited, genetically and
clinically heterogeneous hemorrhagic disorder caused by a deficiency or
dysfunction of the protein called Von Willebrand factor (VWF). This protein is a necessary step in the coagulation cascade, but also involved in the initiation of platelet aggregation for proper blood clotting.
Consequently, defective VWF interaction between platelets and the vessel
wall impairs primary hemostasis. Von Willibrand factor circulates in blood
plasma at concentrations of approximately 10 mg/mL.
Doctors Strike Back
much of the controversy surrounding Maintenance of Certification (MOC), is the question of how much, or even
whether, the process as currently structured actually improves physician
performance and/or patient outcomes.
On February 3, 2015, many physicians
received a surprising email from Richard Baron, MD, MACP, president and chief
executive officer of theAmerican Board of Internal Medicine
(ABIM). Referring to the board’s controversial maintenance
of certification (MOC) program, Baron wrote, “ABIM clearly got it wrong.